Calculate exact reconstitution volumes, insulin units, and doses per vial for any peptide.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide composed of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys). It belongs to the class of growth hormone secretagogues — compounds that stimulate the body's own release of growth hormone (GH) from the anterior pituitary gland. GHRP-6 is not a hormone itself; instead, it mimics the gut peptide ghrelin and triggers a natural, pulsatile release of GH. It was one of the first synthetic GHRPs to be characterized, dating to the 1980s, and it remains a reference molecule for research on the ghrelin axis.
Unlike recombinant growth hormone, which produces a constant, supraphysiological GH level, GHRP-6 works within the body's natural regulatory loops. The pituitary continues to release GH in pulses, and negative feedback through somatostatin and IGF-1 broadly remains intact. For this reason GHRP-6 is frequently used in preclinical research to study the dynamics of GH secretion without fully overriding the pituitary axis.
A defining feature of GHRP-6 — and the one that most clearly separates it from newer analogs such as ipamorelin — is its pronounced appetite stimulation. Because GHRP-6 is a direct ghrelin mimetic, and ghrelin is widely known as the "hunger hormone," it produces a marked increase in appetite in research models, often within 20 to 40 minutes of administration. Depending on the research objective this effect is either desirable or unwanted, and it should be considered when selecting the peptide. GHRP-6 is intended strictly for research purposes.
GHRP-6 exerts its effects primarily through the growth hormone secretagogue receptor (GHS-R1a), the same receptor that endogenous ghrelin binds. This gives rise to several interlocking effects:
GHRP-6 is usually administered in several small doses spread across the day, because the GH response is pulse-bound and the peptide's effect is short-lived. Ramping up gradually from a conservative starting dose is sensible in order to gauge individual tolerability, especially the appetite response.
The most common vial size is 5 mg. Adding 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL (2,500 mcg/mL). The core formulas are: concentration = total mg ÷ BAC volume; volume per dose = target dose ÷ concentration.
At a typical daily schedule of 3 × 100 mcg (300 mcg total), a 5 mg vial lasts roughly 16 to 17 days. Use the GHRP-6 calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose. The calculator also displays the matching IU scale of an insulin syringe.
GHRP-6 is supplied as a lyophilized (freeze-dried) powder in sealed vials. It must be reconstituted with bacteriostatic water (BAC water) before use. Sterile water for injection should not be used for multi-dose vials because it lacks a preservative. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.
GHRP-6 is well characterized in preclinical research and is considered comparatively well tolerated at moderate doses. Because robust long-term human clinical data is lacking, all use remains in the research domain. The observations below come primarily from preclinical models and reports from the research community.
No serious adverse events have been attributed to GHRP-6 in the published research at moderate doses. Given the absence of large-scale human trials, caution is warranted, and consultation with a qualified healthcare professional is strongly recommended.
The most widely described combination pairs GHRP-6 with a GHRH analog such as CJC-1295 (no DAC). The two peptides act at different points of the GH axis and therefore complement one another: a GHRH analog increases the amount of GH that can be released per pulse, while GHRP-6 provides the trigger for the pulse itself and simultaneously dampens the inhibitory action of somatostatin. In research models, co-administration produces a GH response greater than the sum of the individual effects. When both peptides are given at the same time, the GH pulses can be synchronized.
Within the GHRP family, GHRP-6 is distinguished mainly by its side-effect profile. Ipamorelin is considered the most selective GHRP, with little effect on appetite, cortisol, and prolactin, and is often chosen when appetite stimulation is unwanted. GHRP-2 sits in between, with a moderate appetite effect and a slightly stronger GH surge. Hexarelin is the most potent classic GHRP but is the most prone to receptor desensitization. GHRP-6 is selected mainly when its pronounced appetite effect is part of the research objective.
Although GHRP-6 and a GHRH analog are often administered close together in time, each peptide should be reconstituted separately. Mixing them in a single syringe is possible, but their combined stability in solution is not well characterized. Separate injections at adjacent sites eliminate dosing errors and possible interactions. Standalone GHRP-6 use is also common when the research focus is solely the ghrelin axis or appetite regulation.
The most important difference is selectivity. Ipamorelin is a highly selective pentapeptide that releases GH without meaningfully increasing appetite and with minimal effect on cortisol and prolactin. GHRP-6 is a more direct ghrelin mimetic and causes a marked rise in appetite along with potentially stronger effects on secondary axes. If appetite stimulation is desired, GHRP-6 is preferred; if it should be avoided, ipamorelin is the natural choice.
GHRP-6 has a short half-life of roughly two hours and triggers a pulsatile, time-limited release of GH. A single daily dose would produce only one pulse. Research protocols therefore usually split the dose across two or three smaller administrations during the day in order to trigger multiple GH pulses.
Research models observe that a carbohydrate- or fat-rich meal shortly before or after administration can blunt the GH response. For this reason, a gap of about 20–30 minutes from such meals is often chosen. Administration on an empty stomach is regarded as the most favorable condition for a pronounced GH release.
A noticeable appetite stimulation is the most characteristic effect of GHRP-6 because it is a direct ghrelin mimetic. The intensity is dose-dependent and varies between individuals. Some users report that the effect lessens somewhat with continued use. Anyone who wants to avoid an increase in appetite typically chooses a more selective GHRP such as ipamorelin.
GHRP-6 works within the body's natural regulatory loops and does not suppress endogenous GH production in the way exogenous, recombinant growth hormone does. The pituitary continues to release GH in pulses. Feedback mechanisms via IGF-1 and somatostatin nonetheless remain active, and cyclical protocols with breaks are discussed as a precaution given the lack of long-term human data.
In research discussion, cycles of 8 to 12 weeks followed by breaks are common. The breaks are intended to guard against a possible blunting of the GHS-R1a response. Specific durations depend on the model and research question and do not constitute a recommendation for use in humans.
GHRP-6 is classified under the WADA prohibited list among banned GH secretagogues and peptide hormones. Specialized detection assays for GHRPs exist. Athletes subject to WADA-compliant testing should treat GHRP-6 as a prohibited substance and always verify the anti-doping rules currently in force.
GHRP-6 is strictly a research compound. For an overview of the available peptides and their calculators, see the peptide calculator hub. All compounds listed at BergdorfBio are offered strictly for research purposes.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. GHRP-6 is not an approved drug or medical treatment and is provided strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. The regulatory status of peptides varies by jurisdiction. BergdorfBio assumes no liability for the use or misuse of the information presented here.